As of 1:17:23 PM GMT+1. Market Open.
Breakdown
TTM
10/31/2023
10/31/2022
10/31/2021
10/31/2020
Operating Expense
38,791.9980
40,501.5930
24,753.7610
6,936.5070
5,259.7640
Operating Income
-38,791.9980
-40,501.5930
-24,753.7610
-6,936.5070
-5,259.7640
Net Non Operating Interest Income Expense
239.4380
1,468.1470
459.2830
12.1840
-47.4250
Other Income Expense
-375.1210
35.9260
-126.0580
-41.2160
-14.1190
Pretax Income
-38,927.6810
-38,997.5200
-24,420.5360
-6,965.5390
-5,321.3080
Net Income Common Stockholders
-38,927.6810
-38,997.5200
-24,420.5360
-6,965.5390
-5,321.3080
Diluted NI Available to Com Stockholders
-38,927.6810
-38,997.5200
-24,420.5360
-6,965.5390
-5,321.3080
Basic EPS
-0.13
-0.13
-0.09
-0.03
-0.03
Diluted EPS
-0.13
-0.13
-0.09
-0.03
-0.03
Basic Average Shares
303,415.1860
303,332.6860
273,593.1430
245,522.7700
197,287.2310
Diluted Average Shares
303,415.1860
303,332.6860
273,593.1430
245,522.7700
197,287.2310
Total Expenses
38,791.9980
40,501.5930
24,753.7610
6,936.5070
5,259.7640
Net Income from Continuing & Discontinued Operation
-38,927.6810
-38,997.5200
-24,420.5360
-6,965.5390
-5,321.3080
Normalized Income
-38,552.5600
-39,033.4460
-24,294.4780
-6,924.3230
-5,307.1890
Interest Income
632.6030
1,500.2220
577.2850
70.5520
38.8530
Interest Expense
393.1650
32.0750
118.0020
58.3680
86.2780
Net Interest Income
239.4380
1,468.1470
459.2830
12.1840
-47.4250
EBIT
-38,534.5160
-38,965.4450
-24,302.5340
-6,907.1710
-5,235.0300
EBITDA
-38,044.3540
-38,519.8940
-23,862.5360
-6,639.9670
-5,009.8000
Reconciled Depreciation
490.1620
445.5510
439.9980
267.2040
225.2300
Net Income from Continuing Operation Net Minority Interest
-38,927.6810
-38,997.5200
-24,420.5360
-6,965.5390
-5,321.3080
Total Unusual Items Excluding Goodwill
-375.1210
35.9260
-126.0580
-41.2160
-14.1190
Total Unusual Items
-375.1210
35.9260
-126.0580
-41.2160
-14.1190
Normalized EBITDA
-37,669.2330
-38,555.8200
-23,736.4780
-6,598.7510
-4,995.6810
10/31/2020 - 2/8/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
T5O0.DE bioXXmed AG
1.4850
0.00%
BIO3.DE Biotest Aktiengesellschaft
26.80
0.00%
9VC.DE Atai Life Sciences N.V.
1.4070
0.00%
88Q.DE 4basebio PLC
14.60
0.00%
BIO.DE Biotest Aktiengesellschaft
41.40
0.00%
7V0.DE Darwin AG
27.40
+0.74%
VX1.DE Vertex Pharmaceuticals Incorporated
446.15
+1.09%
NP5.DE Newron Pharmaceuticals S.p.A.
7.90
-3.89%
AYJ.DE Valneva SE
1.8360
-1.55%
HPHA.DE Heidelberg Pharma AG
2.4800
0.00%